A new OECD comparison of the European Union and the United States makes one point impossible to ignore: the next phase of biotechnology leadership will not be won in the lab alone. It will be won in the operating system that moves discoveries into markets. Both jurisdictions have world-class research ecosystems. But they do not convert science into commercial scale in the same way. The United States still leads on the classic translation metrics. It files roughly twice as man